AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1776335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6222987 — intervention group
Group type: EXPERIMENTAL
Intervention: All-RN model of nursing care delivery
Number of subjects: 0
Study 6222987 — intervention group
Group type: COMPARATOR
Intervention: Team model of nursing care delivery
Number of subjects: 0
Study 6222987 — intervention group
Group type: COMPARATOR
Intervention: Modular model of nursing care delivery
Number of subjects: 0
Study 31869756 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised medical (including psychiatric) care + cognitive behavioural therapy for dissociative seizures (part of the CODES trial)
Number of subjects: 698
Study 31869756 — intervention group
Group type: COMPARATOR
Intervention: Standardised medical (including psychiatric) care
Number of subjects: 698
Study 30822478 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 110
Study 30822478 — intervention group
Group type: COMPARATOR
Intervention: White Light (WL)
Number of subjects: 110
Study 27998015 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 6051
Study 27998015 — intervention group
Group type: COMPARATOR
Intervention: Al(OH)3 (control)
Number of subjects: 6051
Study 25653009 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercise, 16 weeks, 60 minutes per session, three times a week
Number of subjects: 27
Study 25653009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Tai Chi exercise)
Number of subjects: 27
Study 24403284 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational plan
Number of subjects: 174
Study 24403284 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174
Study 22961514 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPP (transinguinal preperitoneal) repair
Number of subjects: 302
Study 22961514 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 302
Study 18404160 — intervention group
Group type: EXPERIMENTAL
Intervention: ALC group (29 eyes)
Number of subjects: 50
Study 18404160 — intervention group
Group type: COMPARATOR
Intervention: MMC group (21 eyes)
Number of subjects: 50
Study 17060331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1 MAC
Number of subjects: 23
Study 17060331 — intervention group
Group type: COMPARATOR
Intervention: Propofol 4 mug ml(‐1)
Number of subjects: 23
Study 17765963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of perindopril and indapamide
Number of subjects: 11140
Study 14747638 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (acute stress elicited by a standard speech task)
Number of subjects: 59
Study 14747638 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no acute stress)
Number of subjects: 59
Study 10701625 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/ml (1250)
Number of subjects: 120
Study 10701625 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/ml (1300)
Number of subjects: 120
Study 10701625 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg/ml (1350)
Number of subjects: 120
Study 10701625 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 9122857 — intervention group
Group type: EXPERIMENTAL
Intervention: microSelectron-HDR
Number of subjects: 45
Study 9122857 — intervention group
Group type: COMPARATOR
Intervention: Selectron-MDR
Number of subjects: 45
Study 8315152 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward masker presented before the signal (louder tone)
Number of subjects: 0
Study 8315152 — intervention group
Group type: COMPARATOR
Intervention: Forward masker presented before the standard (softer tone)
Number of subjects: 0
Study 8315152 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward masker presented in both intervals of a two-interval trial
Number of subjects: 0
Study 8315152 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward masker presented before the lower frequency tone
Number of subjects: 0
Study 3028362 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta Interferon cream (20,000 iu/g)
Number of subjects: 69
Study 3028362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 30719450 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 120
Study 30719450 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 120
Study 27641367 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative delirium
Number of subjects: 385
Study 27641367 — intervention group
Group type: COMPARATOR
Intervention: No perioperative delirium
Number of subjects: 385
Study 27641367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher S100B levels
Number of subjects: 385
Study 27641367 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 385
Study 27641367 — intervention group
Group type: EXPERIMENTAL
Intervention: Premorbid cognitive impairment
Number of subjects: 385
Study 26111939 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized, web‐based cardiovascular risk service (CVRS) managed by clinical pharmacists for 12 months
Number of subjects: 20
Study 26111939 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 24311828 — intervention group
Group type: EXPERIMENTAL
Intervention: Wu-Ling-San (WLS) formula, 2 gm three times daily for 1 month
Number of subjects: 39
Study 24311828 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 gm three times daily for 1 month
Number of subjects: 39
Study 21865574 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (20 mg/m²/d)
Number of subjects: 95
Study 21865574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 21865574 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (20 mg/kg PO) in animal model
Number of subjects: 95
Study 21865574 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and Paclitaxel (control groups in animal model)
Number of subjects: 95
Study 19659873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral procyanidin + vitamins A, C, E
Number of subjects: 60
Study 19659873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16626577 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin eluting stent (Cypher)
Number of subjects: 416
Study 16626577 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel eluting stent (TAXUS)
Number of subjects: 416
Study 15182401 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite breakfast meals
Number of subjects: 28
Study 11843249 — intervention group
Group type: EXPERIMENTAL
Intervention: SIR-Spheres plus chemotherapy (HAC)
Number of subjects: 74
Study 9684188 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral specific hyposensitization treatment
Number of subjects: 30
Study 9684188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7849967 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol DA-20% (FDA) intravenous infusion at 30 cc/kg
Number of subjects: 55
Study 7849967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FDA treatment)
Number of subjects: 55
Study 3370307 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C‐DMPP with a high-fat meal
Number of subjects: 18
Study 3370307 — intervention group
Group type: EXPERIMENTAL
Intervention: 3H‐DMPP with a high-fat meal
Number of subjects: 18
Study 3370307 — intervention group
Group type: COMPARATOR
Intervention: 3H‐DMPP in fasting state
Number of subjects: 18
Study 3370307 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPP and its metabolites
Number of subjects: 18
Study 3370307 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolites of DMPP
Number of subjects: 18
Study 30298685 — intervention group
Group type: EXPERIMENTAL
Intervention: High opioid consumption trajectories
Number of subjects: 152
Study 30298685 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest opioid consumption trajectory
Number of subjects: 152
Study 30298685 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and baseline levels of anxiety
Number of subjects: 152
Study 30298685 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 152
Study 29180457 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker (Bbl)
Number of subjects: 1873
Study 25343235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary advice, coaching, and exercise during pregnancy)
Number of subjects: 157
Study 23949839 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-based PN service
Number of subjects: 59
Study 23949839 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 59
Study 20726814 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 2617
Study 20726814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2617
Study 19905933 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ-SP
Number of subjects: 61
Study 19905933 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-AQ
Number of subjects: 61
Study 19905933 — intervention group
Group type: COMPARATOR
Intervention: AL
Number of subjects: 61
Study 16783479 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-24 (500 mg once daily)
Number of subjects: 24
Study 16783479 — intervention group
Group type: EXPERIMENTAL
Intervention: AM-24 (240 mg and 350 mg doses also administered)
Number of subjects: 24
Study 15145629 — intervention group
Group type: EXPERIMENTAL
Intervention: Banked breastmilk
Number of subjects: 216
Study 15145629 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater proportion of human milk intake in infancy
Number of subjects: 216
Study 15145629 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 216
Study 11283536 — intervention group
Group type: EXPERIMENTAL
Intervention: CoStasis Surgical Hemostat
Number of subjects: 318
Study 11283536 — intervention group
Group type: COMPARATOR
Intervention: Control (manual compression)
Number of subjects: 318
Study 9060084 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic urethrocystopexy
Number of subjects: 45
Study 9060084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubococcygeal repair
Number of subjects: 45
Study 9060084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgical techniques (treated as one group)
Number of subjects: 45
Study 9060084 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved/Failure group (one year after surgery)
Number of subjects: 45
Study 9060084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured women
Number of subjects: 45
Study 9060084 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of surgical outcome
Number of subjects: 45
Study 8445423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 15
Study 8445423 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen plus fenretinide 100, 200, 300, or 400 mg/d
Number of subjects: 15
Study 8445423 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen plus fenretinide
Number of subjects: 15
Study 2429008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordarone
Number of subjects: 80
Study 2429008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmosine
Number of subjects: 80
Study 2429008 — intervention group
Group type: COMPARATOR
Intervention: Mexitil
Number of subjects: 80
Study 2429008 — intervention group
Group type: COMPARATOR
Intervention: Rhytmilen
Number of subjects: 80
Study 2429008 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 80
Study 2429008 — intervention group
Group type: COMPARATOR
Intervention: Finoptin
Number of subjects: 80
Study 2429008 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 80
Study 31613432 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 1000
Study 31613432 — intervention group
Group type: COMPARATOR
Intervention: Usual oxygen therapy
Number of subjects: 1000
Study 29861249 — intervention group
Group type: EXPERIMENTAL
Intervention: Zumba dancing performed twice a week for 12 weeks
Number of subjects: 19
Study 26787201 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised case management with a personalised booklet ('Passport') and up to four brief telephone contacts in the first 4 weeks post-release
Number of subjects: 1325
Study 26787201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1325
Study 26787201 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised case management
Number of subjects: 1325
Study 25711324 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD prevalence among ART-naïve adults
Number of subjects: 4637
Study 25711324 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine protein ≥ 1+
Number of subjects: 4637
Study 25711324 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR < 60 mL/min/1.73 m²
Number of subjects: 4637
Study 25711324 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics associated with CKD
Number of subjects: 4637
Study 23902955 — intervention group
Group type: EXPERIMENTAL
Intervention: PDF (per 100 mL: 67 kcal, 1.7 g protein, 65 mg calcium, 38 mg phosphorus, 56 IU vitamin D)
Number of subjects: 139
Study 23902955 — intervention group
Group type: COMPARATOR
Intervention: TF (per 100 mL: 67 kcal, 1.47 g protein, 50 mg calcium, 30 mg phosphorus, 48 IU vitamin D)
Number of subjects: 139
Study 23902955 — intervention group
Group type: COMPARATOR
Intervention: HM
Number of subjects: 139
Study 23902955 — intervention group
Group type: EXPERIMENTAL
Intervention: PDF
Number of subjects: 139
Study 21917892 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC) with efavirenz (EFV)
Number of subjects: 0
Study 21917892 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC) with atazanavir/ritonavir (ATV/r)
Number of subjects: 0
Study 21917892 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV)
Number of subjects: 0
Study 21917892 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir DF/emtricitabine (TDF/FTC) with atazanavir/ritonavir (ATV/r)
Number of subjects: 0
Study 21917892 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine (ABC/3TC)
Number of subjects: 0
Study 21917892 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir DF/emtricitabine (TDF/FTC)
Number of subjects: 0
Study 18946504 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright images of faces
Number of subjects: 0
Study 18946504 — intervention group
Group type: COMPARATOR
Intervention: Inverted images of faces
Number of subjects: 0
Study 18946504 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright images of houses
Number of subjects: 0
Study 18946504 — intervention group
Group type: COMPARATOR
Intervention: Inverted images of houses
Number of subjects: 0
Study 18946504 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright images of bodies
Number of subjects: 0
Study 18946504 — intervention group
Group type: COMPARATOR
Intervention: Inverted images of bodies
Number of subjects: 0
Study 17165299 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-based resilient denture liner (SR)
Number of subjects: 28
Study 17165299 — intervention group
Group type: COMPARATOR
Intervention: Conventional heat‐activated acrylic resin (AR)
Number of subjects: 28
Study 14708472 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 10
Study 14708472 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 20 mg
Number of subjects: 10
Study 14708472 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 10
Study 14708472 — intervention group
Group type: COMPARATOR
Intervention: Basal (no treatment)
Number of subjects: 10
Study 11062278 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stroke unit care integrated with geriatric stroke unit care continuum
Number of subjects: 249
Study 11062278 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 249
Study 9709269 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 8269207 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 84
Study 3623787 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfusion of autologous blood (1350 ml)
Number of subjects: 6
Study 3623787 — intervention group
Group type: COMPARATOR
Intervention: Control group (six well‐trained skiers)
Number of subjects: 6
Study 31691053 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (G3, n = 25), 400 mW, continuous mode, 5 s per point, 23 points, total energy per session 46 J
Number of subjects: 76
Study 31691053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (G2, n = 26), generator probe type 3, working time per point 5 s, 23 points, application time 1 min and 55 s
Number of subjects: 76
Study 31691053 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1, n = 26)
Number of subjects: 76
Study 29590338 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-focused self-help course (n = 65)
Number of subjects: 128
Study 29590338 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (n = 63)
Number of subjects: 128
Study 28637773 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge formula (PDF)
Number of subjects: 79
Study 28637773 — intervention group
Group type: COMPARATOR
Intervention: Term formula (TF)
Number of subjects: 79
Study 25704754 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated computer-based procedure (CBP)
Number of subjects: 60
Study 25704754 — intervention group
Group type: COMPARATOR
Intervention: Existing individual computer-based procedure (CBP)
Number of subjects: 60
Study 24139003 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pressure release and 10 s passive stretch
Number of subjects: 22
Study 24139003 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 22
Study 21118369 — intervention group
Group type: EXPERIMENTAL
Intervention: HA330 hemoperfusion treatment (N=24)
Number of subjects: 44
Study 21118369 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (N=20)
Number of subjects: 44
Study 18230016 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast symptoms and greater cancer worry
Number of subjects: 3758
Study 18230016 — intervention group
Group type: EXPERIMENTAL
Intervention: Random change
Number of subjects: 3758
Study 16630748 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg)
Number of subjects: 69
Study 16630748 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 69
Study 16630748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 14600520 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC125 (900 mg twice daily for 7 days)
Number of subjects: 19
Study 14600520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 14675010 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar LV from the cardiac venous lead
Number of subjects: 19
Study 14675010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar LV using the tip electrode in the cardiac vein as the cathode and the ring electrode of the RV lead as the anode
Number of subjects: 19
Study 14675010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar RV from the RV lead
Number of subjects: 19
Study 14675010 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar split cathodal stimulation of the cardiac venous and RV leads
Number of subjects: 19
Study 14675010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar split cathodal stimulation of the cardiac venous and RV leads
Number of subjects: 19
Study 10080589 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine at 2,510 mg/m2/d for 2 weeks followed by a 1-week rest period, repeated in 3-week cycles.
Number of subjects: 163
Study 7813270 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized norepinephrine (NE) 0.04 mg
Number of subjects: 12
Study 7813270 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 1763589 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg bolus followed by 5 mg infusion over 1 h) + TENS (low or high frequency)
Number of subjects: 60
Study 1763589 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (5 mg)
Number of subjects: 60
Study 1763589 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (0.15 mg)
Number of subjects: 60
Study 6410971 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) 1 mg intravenously as a bolus dose, followed by 1 mg infused over 5 minutes, then 1 mg intravenously every 12 hours for 3 days
Number of subjects: 13
Study 6410971 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 13
Study 3966338 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 9
Study 3966338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study 28960164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI) delivered by a supervised sleep educator
Number of subjects: 159
Study 28960164 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 159
Study 27329400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg, 3 times a day for 16 weeks
Number of subjects: 28
Study 27329400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26194932 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic voluntary hyperpnea to task failure (FT+)
Number of subjects: 12
Study 26194932 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study 23873891 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost ophthalmic solution 0.03%
Number of subjects: 278
Study 23873891 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 278
Study 21914755 — intervention group
Group type: COMPARATOR
Intervention: Sham group (2 mL 0.9% saline)
Number of subjects: 133
Study 21914755 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline group (30 mL 0.9% saline)
Number of subjects: 133